Abstract: A method for controlling noxious organisms in a field of soybean or corn, comprising the steps of: treating soybean or corn seeds with at least one neonicotinoid compound selected from the group consisting of clothianidin, thiamethoxam, imidacloprid, dinotefuran, nitenpyram, acetamiprid, and thiacloprid, and treating the field with at least one PPO inhibitor compound selected from the group consisting of flumioxazin, sulfentrazone, saflufenacil, oxyfluorfen, and 3-(4-chloro-6-fluoro-2-trifluoromethylbenzimidazol-7-yl)-1-methyl-6-trifluoromethyl-2,4-(1H,3H)pyrimidinedione before or after the soybean or corn seeds treated with the neonicotinoid compound are sown in the field.

Abstract: Herbicide combinations (A)+(B), if appropriate in the presence of safeners, with an effective content of (A) broad-spectrum herbicides from the group (A1) glufosinate (salts) and related compounds (A2) glyphosate (salts) and related compounds such as sulfosate, (A3) imidazolinones such as imazethapyr, imazapyr, imazaquin, imazamox or their salts and (A4) herbicidal azoles from the group of the protoporphyrinogen oxidase inhibitors (PPO inhibitors) and (B) one or more herbicides from the group consisting of (B0) one or more structurally different herbicides from the abovementioned group (A) or (B1) foliar- and soil-acting herbicides effective against selectively in rice monocotyledonous and dicotyledonous harmful plants (residual action) or (B2) herbicides which are effective selectively in rice against dicotyledonous harmful plants and/or sedges, and/or (B3) foliar-acting herbicides which are effective selectively in rice against monocotyledonous harmful plants, and/or (B4) foliar- and soil-acting herbi

Abstract: Efficacious herbicidal compositions comprising a derivatized saccharide surfactant and an amine oxide surfactant are described. The compositions are characterized as having low toxicity and are readily biodegradable.

Abstract: The present invention relates to a method for controlling coniferous plants, in particular naturally seeded coniferous plants (wildling conifers), wherein an effective amount of at least one herbicide selected from the group consisting of sulfentrazone, carfentrazone, their agriculturally acceptable salts and their agriculturally acceptable derivatives is applied to the coniferous plants to be controlled or to their parts, such as roots, leaves, seeds or germinants.

Abstract: A description is given of 4-(4-haloalkyl-3-thiobenzoyl)pyrazoles of the formula (I) and of their use as herbicides. In this formula (I), X, Y, R1, R2, R3, and R4 are radicals such as hydrogen and organic radicals such as alkyl.

Abstract: Novel articles and methods to fabricate same with self-assembled nanodots and/or nanorods of a single or multicomponent material within another single or multicomponent material for use in electrical, electronic, magnetic, electromagnetic and electrooptical devices is disclosed. Self-assembled nanodots and/or nanorods are ordered arrays wherein ordering occurs due to strain minimization during growth of the materials. A simple method to accomplish this when depositing in-situ films is also disclosed. Device applications of resulting materials are in areas of superconductivity, photovoltaics, ferroelectrics, magnetoresistance, high density storage, solid state lighting, non-volatile memory, photoluminescence, thermoelectrics and in quantum dot lasers.

Abstract: According to various embodiments, a method is provided that comprises washing an array of DNA-coated beads on a substrate, with a wash solution to remove stacked beads from the substrate. The wash solution can include inert solid beads in a carrier. The DNA-coated beads can have an average diameter and the solid beads in the wash solution can have an average diameter that is at least twice the diameter of the DNA-coated beads. The washing can form dislodged DNA-coated beads and a monolayer of DNA-coated beads. In some embodiments, first beads for forming an array are contacted with a poly(ethylene glycol) (PEG) solution comprising a PEG having a molecular weight of about 350 Da or less. In some embodiments, slides for forming bead arrays are provided as are systems for imaging the same.

Abstract: The invention relates to a method for analysing interactions of a nucleic acid with at least one polypeptide, comprising (a) providing a reaction vessel with a composition comprising cross-linked complexes comprising at least one nucleic acid and at least one polypeptide; (b) immobilizing at least part of the cross-linked complexes to the reaction vessel; (c) at least partially reversing said cross-links in said immobilized complexes by performing a heat incubation step thereby at least partially releasing the nucleic acids from the complexes; (d) analyzing the released nucleic acid. wherein steps (a) to (d) are performed in one reaction vessel. Also provided are specific reaction vessels and kits.

Abstract: A cement composition or method of using the cement composition in a subterranean formation, the composition having: (A) cement; (B) water; and (C) a polymer, wherein the polymer: (i) comprises a monomer or monomers selected from the group consisting of epoxysuccinic acid, a substituted epoxysuccinic acid, and an alkali metal salt, alkaline earth metal salt, or ammonium salt of any of the foregoing, and any combination of any of the foregoing; (ii) has the following characteristics: (a) is water soluble; and (b) is biodegradable; and (iii) is capable of providing: (a) a thickening time of at least 2 hours for a test composition at a temperature of 190° F. and a pressure of 5,160 psi; and (b) an initial setting time of less than 24 hours for the test composition at a temperature of 217° F. and a pressure of 3,000 psi.

Abstract: A gear oil additive composition and gear oil composition comprising a organic polysulfide having at least 30 wt % of a dialkyl polysulfide compound or mixture of dialkyl polysulfide compounds, a thiadiazole; and at least one ashless phosphorus-containing wear inhibitor compound is disclosed as having low yellow corrosion in axles and transmissions.

Abstract: A liquid extreme pressure agent for use in lubricating compositions where the lubricating compositions comprise an oil of lubricating viscosity and the reaction product of: (a) a thiazole; (b) a composition comprising a carboxylic acid, a phosphorus containing acid or salt, or combinations thereof; and (c) an amine containing one or more branched hydrocarbyl groups. The invention also provides an additive composition comprising the reaction product described above and a process for making lubricating compositions, including greases, from the reaction product.

Abstract: The hand soap bar with tether is a bar of hand soap having a built-in tether. The tether includes an elastic band that can be attached to a user's wrist. An anchor member is encased in the soap bar. One end of the tether is attached to the anchor member. An elastic loop defines the other end of the tether.

Abstract: A medical instrument cleaning concentrate and method for cleaning medical equipment. The concentrate contains an active ingredient consisting essentially of (i) a biofilm permeation agent and (ii) a nonionic alkoxylated alcohol surfactant having an HLB ranging from about 5 to about 8, wherein a ratio of (i) to (ii) in the concentrate ranges from about 2:1 to about 4:1.

Abstract: The use of ferric hydroxycarboxylate as a chelator and builder for cleaning compositions is disclosed. The cleaning composition may be formulated for warewashing, laundering, and for other means of removing soils and includes a ferric hydroxycarboxylate, an alkalinity source and a surfactant system. The cleaning composition has a pH of between about 9 and about 12.

Abstract: Article for use in a dishwashing machine, which comprises a water-soluble glass or ceramic composition effective to reduce corrosion of glassware and at least one surfactant containing composition, wherein the amount of the glass or ceramic composition is within the range of 5 to 95 wt. % and the amount of the surfactant is in the range of 5 to 95 wt. %, both percentages based on the weight of the article.

Abstract: The present application relates to care polymers and fabric and home care compositions comprising such care polymers, as well as processes for making and using such care polymers and such compositions. The performance of the care polymers that Applicants teach, can be further increased by following the emulsification teaching of the present specification and/or combining such care polymers with silicone materials.

Abstract: This invention relates to a foam control composition comprising: (A) a silicone antifoam comprising (i) an organopolysiloxane having at least one silicon-bonded substituent of the formula X—Ar, wherein X represents a divalent aliphatic group bonded to silicon through a carbon atom and Ar represents an aromatic group, (ii) an organosilicon resin having the formula R1aSiO(4-a)/2 where R1 represents a hydrocarbon, a hydrocarbonoxy or a hydroxyl group and a has an average value of 0.5 to 2.4, and (iii) a hydrophobic filler; and (B) an organopolysiloxane resin having at least one polyoxyalkylene group in which the organopolysiloxane resin comprises tetrafunctional siloxane units having the formula SiO4/2 and monofunctional siloxane units having the formula R23SiO1/2, wherein the total number of tetrafunctional siloxane units in the resin is at least 50% based on the total number of siloxane units, and R2 represents a hydrocarbon group.

Abstract: A method of manufacturing a detergent composition comprising combining a plurality of components suitable for producing a detergent block which is water soluble into a fluid mixture. A mold assembly is provided which has a first mold component and a second mold component. The first and second mold components define a mold assembly having a body and a bottom. The body includes an outer wall, a bottom and outer wall which defines a mold interior. The fluid mixture is presented into the mold assembly and allowed to harden into at least a partially solid state within the mold defining a solid soluble, consumable detergent block. Once the block is at least partially cured, the first and second mold components are separated exposing the solid soluble, consumable detergent block to the ambient environment. Water soluble indicia are positioned onto the soluble consumable detergent block.

Abstract: The present invention provides a hydrophilicity-restoring agent for removing inorganic matter from a hydrophilic surface whose hydrophilicity has been reduced by the adhesion of the inorganic matter to thereby restore the hydrophilicity of the hydrophilic surface, and provides a method for restoring the hydrophilicity of a hydrophilic surface using the hydrophilicity-restoring agent. A gel of a hydrophilicity-restoring agent is prepared by mixing a thickener such as polyethylene glycol and xanthan gum with an aqueous solution in which a ligand such as citric acid to form a chelate complex is dissolved. The hydrophilicity of the hydrophilic surface is restored by applying the hydrophilicity-restoring agent to the hydrophilic surface with a reduced hydrophilicity and removing the hydrophilicity-restoring agent after an appropriate lapse of time.

Abstract: Liquid cleaning compositions are described that comprise sulfo-estolide (SE) salts, particular sodium, lithium or ammonium salts of sulfo-estolides, and alkyl ester sulfonates. The liquid cleaning compositions are clear, stable and substantially free of precipitates due to the use of sodium, lithium or ammonium salts of sulfo-estolide rather than a potassium sulfo-estolide salt in the composition. The liquid cleaning compositions also have a total combined amount of saturated C16 and C18 fatty acids of less than about 5% by weight to prevent the formation of precipitates in the composition.

Abstract: Short oligopeptides are provided which are capable of binding to the epidermal growth factor receptor on the surface of human tumor cells. Methods for using the peptides as targeting moieties in more complex compositions, such as conjugates of cytoxins, and/or structures, such as liposomal structures, for the purposes of drug delivery are also provided.

Abstract: Disclosed herein are compounds of general formula (I): wherein A, B, R1 and R2 are as defined in the specification, and their use as pharmaceuticals.

Abstract: The present invention provides AMPAR excitotoxicity mediating polypeptides comprising the GluR2 NT1-3-2 (Y142-K172) amino acid sequence (SEQ ID NO:1) or the GAPDH(2-2-1-1) (I221-E250)amino acid sequence (SEQ ID NO:2). Also disclosed are nucleotide sequences encoding the polypeptides, methods of inhibiting GAPDH association with the GluR2 subunit or p53. Methods of inhibiting AMPA receptor mediated excitotoxicity using the polypeptides and nucleic acids are also disclosed.

Abstract: Enclosed is an antagonist, which includes a peptide chain represented by an amino acid sequence. The amino acid sequence has a short sequence, C-X1X2X3X4X5-N, which is situated before and neighbored to the third cysteine (Cys, C) of the N-terminus, wherein X1 is an amino acid with aromatic ring, hydrophobic property or long chain, and X2, X3, X4 and X5 are glutamine (G), serine (S), alanine (A) and proline (P) respectively. In one embodiment, X1 is phenylalanine (F). The present antagonists can be used to inhibit or treat with the diseases caused by the activated cells expressing CXCR1 and/or CXCR2 receptor, for example, the acute or chronic inflammatory reaction induced with polymorphonuclear neutrophils (PMNs) expressing CXCR1 and/or CXCR2 receptor, and angiogenesis accompanied by tumor growth inhibition.

Abstract: A method for the treatment of cardiovascular disease or disorder in a subject in need thereof, the method comprising the steps of administering an ApoA1 mimetic that is capable of promoting cholesterol efflux from lipid loaded cells in the subject, wherein the ApoA1 mimetic has an amino acid sequence that includes at least a portion of the amino acid sequence of ApoA1 or a mimetic of ApoA1 that contains at least one tryptophan, at least one tryptophan from the ApoA1 or mimetic of the ApoA1 being substituted with an oxidant resistant amino acid in the amino acid sequence of the ApoA1 mimetic.

Abstract: The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by inhibiting a hyperstabilized c-met protein.

Abstract: Fluorescent metal nanoclusters were prepared.

Abstract: The present invention provides novel compounds that have been demonstrated to be modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, iso forms and variants thereof). These compounds are useful as antagonists of the ghrelin receptor as well as inverse agonist, partial agonist or a combination of these activities as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, diabetes, central nervous system disorders, genetic disorders, and hyperproliferative disorders.

Abstract: The present invention provides the use of ?arrestin2 protein or its up-regulators for manufacturing a composition for the prevention or treatment of insulin resistance or related disease in mammals. The reagents and the kits for the specific identification of ?arrestin2 protein or its coding gene or transcript are also provided which can be used in diagnosis of insulin resistance or related diseases.

Abstract: Protracted GLP-1 compounds and therapeutic uses thereof.

Abstract: A method that includes a measurement of hemoglobin or hematocrit with a measurement of hemodynamic parameters to monitor and/or control a modality of treatment of a patient suffering from anemia.

Abstract: An artificial decapeptide for inducing vitellogenesis in fish, being an analogue of gonadotropin-releasing hormone of chicken is set forth in SEQ ID NO: 2. The artificial decapeptide can be further developed and manufactured into a preparation, which is capable of inducing vitellogenesis in fish. With the implantation of the preparation into body cavity or body wall of bony fish, the induction of vitellogenesis and ovum maturation in bony fish can be successfully achieved.

Abstract: The invention relates to a method for stabilizing a bulk solution of recombinant protein for frozen storage, which comprises providing a partially-purified solution of recombinant protein which has a monovalent salt concentration of at least 100 mM, and adding a carbohydrate to said solution in an amount sufficient that, upon freezing, the solution has a glass transition temperature of ?56° C. or higher.

Abstract: The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules.

Abstract: Provided are storage containers for proteinaceous pharmaceutical compositions which are characterized in, among other things, comprising (i) a wall portion, wherein an inner wall material thereof is selected from silica-coated glass, silicone-coated glass, polymers of non-cyclic olefins, cycloolefin polymers and cycloolefin/linear olefin copolymers and (ii) one or more closure portions not constituting part of the wall portion, and which contains a formulation of a protein. Also provided are new methods of storing proteinaceous compositions. In one aspect, the stored protein is characterized as having an amino-terminal ?-carboxyglutamic acid (Gla) domain with 9-12 Gla residues.

Abstract: The present invention relates to the expression and regulating growth factors in chrondrocytes and developing cartilage, particularly granulin-epithelin precursor (GEP). The invention relates to the modulation and manipulation of these growth factors, GEP, and/or the molecules they interact with, for instance COMP, in cartilage disorders, including arthritis. Assays and screening methods for the determination of the expression and activity of GEP, or of GEP-COMP, are provided, including for screening for the presence or extent of cartilage or arthritic disease and for identifying modulators or compounds/agents for treatment or prevention of cartilage or arthritic diseases.

Abstract: The invention provides methods of treating or effecting prophylaxis of a patient having or at risk of developing symptoms of anxiety in which an effective regime of an agent that inhibits specific binding of PSD95 to an NMDA receptor is administered to a patient.

Abstract: Use of 1-phenyl-3-dimethylaminopropane compounds for the production of medicaments for treating neuropathic pain, preferably polyneuropathic pain, also preferably diabetic neuropathic pain, more preferably diabetic peripheral neuropathic pain, and furthermore preferably for treating diabetic peripheral neuropathy.

Abstract: The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure: The compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions.

Abstract: Disclosed herein are compositions and methods for and involving selectively targeting tumor lymphatics.

Abstract: This invention provides polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each binds different regions on the target molecule. The ligands are joined directly or through a linker thereby forming a polydentate moiety that typically binds the target molecule with high selectivity and avidity.

Abstract: A composition comprising a therapeutically effective amount of cyclosporin A, a blend of oils having a specific gravity of from 0.90 to 1.07, and a surfactant is disclosed herein.

Abstract: The present invention is related to methods of generating adaptive biochemical signatures in live cells and the use of said signatures to identify diagnostic and therapeutic modalities for human disease. The methods described herein comprise contacting a provocative agent to live cells and measuring and analyzing adaptive readouts. The methods of the invention may be used for therapeutic or diagnostic purposes.

Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.

Abstract: The present invention is directed to the use of a class of peptide compounds for treating tumor pain, in particular bone cancer pain, for treating chemotherapy-induced pain and for treating nucleoside-induced pain.

Abstract: This disclosure relates generally to methods and pharmaceutical compositions useful in treating pulmonary hypertension. In one embodiment, for example, the disclosure provides a method for treating pulmonary hypertension comprising administering a therapeutically effective dose of a carbonic anhydrase inhibitor to a patient in need of treatment. The disclosure finds utility in the fields of medicine and pharmacology.

Abstract: The present invention relates to lipoteichoic acid T for use in treating pleural effusion or pneumothorax. The present invention also relates to the use of lipoteichoic acid T (LTA-T) in the manufacture of a medicament for treating pleural effusion or pneumothorax. The present invention also relates to a kit comprising a pharmaceutical composition comprising lipoteichoic acid T and instructions indicating that the composition is for use as a pleurodesis agent. In addition, the present invention relates to a method of treating pleural effusion or pneumothorax comprising administration of lipoteichoic acid T to a subject.

Abstract: A method is described for treating inflammatory bowel disease in a subject in need thereof. The method comprises administering a formulation comprising at least one ganglioside to the subject, wherein the formulation comprises at least about 50% GD3 by weight of total ganglioside content.

Abstract: Pharmaceutical compositions and methods for protecting against atrophy of pancreatic islets in a mammal with metabolic syndrome, prediabetes or diabetes are disclosed. The method comprises administering to the mammal a pharmaceutical composition comprising a compound having a chemical structure of formula (I) in an effective amount and a pharmaceutically acceptable carrier: wherein R is H or COCH2COOH; m=3 or 4; n=0 or 1; o=2; and p=1 or 2.

Abstract: A spinosyn or a physiologically acceptable derivative or salt thereof for promoting or accelerating wound healing in humans.